A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Mar 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system responds to a type of cancer treatment called immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). The researchers want to understand the environment around the tumor at a very detailed level before the patients receive the treatment. By doing this, they hope to identify new indicators, or "biomarkers," that can help determine how well the treatment works and whether patients might experience side effects. Additionally, they will look at blood samples and fluid from the lungs to find non-invasive ways to monitor both the effectiveness and potential toxicity of the treatment.

To be eligible for this trial, participants must be adults aged 18 and older, have a confirmed diagnosis of NSCLC, and be receiving their first line of treatment according to healthcare guidelines. They should not be participating in other clinical trials and must provide informed consent to join. Those who take part can expect to undergo tests that analyze their immune cells before and during treatment, which may help improve future cancer therapies. It's important to know that this study is still recruiting participants, so there is an opportunity to contribute to valuable research in lung cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Adult M/F/X (\>= 18 years)
• • Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)
• • Patients receiving first-line treatment per guidelines
• • Not included in other clinical trials
• • Signed informed consent form
• Exclusion criteria:
• • • Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.